Results of Rosiglitazone Therapy in Patients with Thyroglobulin-Positive and Radioiodine-Negative Advanced Differentiated Thyroid Cancer

Kebebew, Electron; Lindsay, Sheila; Clark, Orlo H.; Woeber, Kenneth A.; Hawkins, Randall A.; Greenspan, Francis S.

doi:10.1089/thy.2008.0371

Cited by 75 publications

(51 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Grade 4: myocardial infarction and small-cell lung cancer Capdevila et al (2012) Grade 3: HFS (20) been studied as well, mainly comprising rosiglitazone, vorinostat, thalidomide, celecoxib, and selumetinib (Mrozek et al 2006, Ain et al 2007, Kebebew et al 2009, Woyach et al 2009, Ho et al 2013. Though most of them exhibited modest efficacy, selumetinib, a MAPK kinase (MEK) 1 and MEK 2 inhibitor, increased the uptake of iodine-124 in 12 of the 20 patients (60%).…”

Section: Discussionmentioning

confidence: 99%

Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis

Shen¹,

Qiu²,

Luo³

2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

The advent of biologically targeted agents and increased understanding of thyroid carcinogenesis have generated much interest in the development of biologically targeted therapeutic agents for thyroid cancer. Among them, sorafenib is the most commonly studied drug. The current meta-analysis was carried out to estimate the efficacy and safety of sorafenib administered in radioiodine-refractory differentiated thyroid cancer patients. An electronic search was conducted using PubMed/MEDLINE and EMBASE. Statistical analyses were carried out using either random-effects or fixed-effects models according to heterogeneity. All the statistical analyses were carried out using the Stata version 12.0 software. Seven eligible studies were identified. The final results indicated that 22% of the patients (95% CI: 15-28) achieved a partial response. Hand-foot syndrome, diarrhea, fatigue, rash, weight loss, and hypertension were the most frequently observed adverse effects (AEs) associated with sorafenib use and the incidence of these AEs (all grades) was 80% (95% CI: 68-91), 68% (95% CI: 59-77), 67% (95% CI: 57-78), 66% (95% CI: 50-82), 52%(95% CI: 33-72), and 31% (95% CI: 21-42) respectively. Sixty-two percent (95% CI: 36-89) patients required dose reductions due to toxicity of sorafenib. As far as PR and AEs are concerned, the results of this meta-analysis indicate that sorafenib has a modest effect in patients with radioiodine-refractory differentiated thyroid cancer and the high incidence of AEs associated with this agent may affect the quality of patients' lives. Though the use of sorafenib in the treatment of radioiodinerefractory differentiated thyroid cancer is considered promising by most physicians working in this field, more effective agents with less toxicity and cost are still needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis

Shen¹,

Qiu²,

Luo³

2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…An in vitro study of thiazolidinediones showed an increase in differentiation in the human thyroid follicular carcinoma cell lines [37], and in vivo studies of thiazolidinediones reported that a quarter of patients with radioiodine negative DTC achieved a positive radioiodine scan [38,39], in 1 of these studies, no CR or PR was obtained at 3 months after treatment according to RECIST criteria [39]. Several studies have reported that HDAC inhibitors induced sodium iodide symporter gene expression and radioiodine uptake [40,41].…”

Section: Discussionmentioning

confidence: 99%

Response of Retinoic Acid in Patients with Radioactive Iodine-Refractory Thyroid Cancer: A Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

Purpose: The purpose of this study was to evaluate the response of retinoic acid (RA) in radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Methods: Systematic searches of MEDLINE (from inception to December 2016) and of EMBASE (from inception to December 2016) were performed for English-language publications on thyroid cancer treated with RA. Studies were classified according to the response criteria used: (1) ¹²³I or ¹³¹I whole body scintigraphy (WBS), (2) serum thyroglobulin (Tg) level, (3) the response evaluation criteria in solid tumors (RECIST) version 1.0, and (4) World Health Organization (WHO) criteria. Results: Disease response rates as determined by WBS ranged widely between 6.2% and 46.1% with a pooled disease response rate of 27.6% (95% confidence interval: 21.7-34.0%). Response rates as determined by Tg level ranged from 56.6% to 83.3% (pooled response rate 61.3% (51.0-70.9%)), RECIST response rates from 0% to 45.5% (pooled response rate 17.0% (1.4-44.5%)), and according to WHO criteria, the pooled response rate was 30.8% (12.7-52.7%). Conclusions: A minority of patients with RAI-refractory DTC respond to RA treatment.

show abstract

“…However, the same group reported somewhat disappointing results several years later. Although rosiglitazone induced an increase in iodine uptake or decrease in serum Tg to some degree in 5/20 patients, a clinically significant response such as CR (complete response) or PR was not observed [46]. Thus, the clinical trials so far have not demonstrated very satisfactory results, but selection of more specific indications may be an answer.…”

Section: Pparγ Agonistsmentioning

confidence: 97%

“…So far, rosiglitazone is the only drug that has been tried in thyroid cancer patients [45][46][47][48][49]. However, as troglitazone was reported to be more effective than any other thiazolinedione in a cell study [43], appropriate drug selection will be an issue.…”

Section: Pparγ Agonistsmentioning

confidence: 99%

Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers

Paeng

Kang

Park

et al. 2011

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Thyroid cancer is one of the most rapidly increasing cancers in many countries. Although most thyroid cancers are differentiated cancers and easily treated with radioiodine (RI), a portion of differentiated and undifferentiated cancers is refractory not only to RI therapy, but also to radiotherapy and chemotherapy. Thus, various alternative therapies have been tested in RI-refractory thyroid cancers. These alternative therapies include two major categories: redifferentiation therapy and recent molecular target therapy. Several clinical trials have investigated these therapies. They demonstrated potential effects of the therapies, although the results have been somewhat limited so far. Thus, the future strategy for undifferentiated thyroid cancers will involve individualized, lesion-specific, and combined therapy. In this review, the basic mechanism of each redifferentiation and molecular target therapy is discussed, and results of recent clinical trials using these therapeutic agents are summarized.

show abstract

Results of Rosiglitazone Therapy in Patients with Thyroglobulin-Positive and Radioiodine-Negative Advanced Differentiated Thyroid Cancer

Cited by 75 publications

References 21 publications

Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis

Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis

Response of Retinoic Acid in Patients with Radioactive Iodine-Refractory Thyroid Cancer: A Meta-Analysis

Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers

Contact Info

Product

Resources

About